How Mesenchymal Stem Cells May Help Immune Balance in Relapsing-Remitting MS

In this episode, we explore how mesenchymal stem cells (MSCs) may help regulate the immune system in relapsing-remitting multiple sclerosis and what current research reveals about this emerging therapy.

You’ll learn:

• What relapsing-remitting MS is and how it affects the immune system and nerve function
• How mesenchymal stem cells (MSCs) interact with T cells and B cells to support immune balance
• Why does MSC therapy focus on immune modulation instead of suppressing the immune system
• Key benefits, including reduced inflammation, neuroprotective effects, and tissue repair support
• How MSC therapy compares to hematopoietic stem cell transplant in terms of safety and approach
• What clinical trials show about effectiveness, symptom improvement, and long-term potential
• Important considerations, including safety, cost, and choosing regulated treatment programs

While mesenchymal stem cell therapy shows promising results in early research, it remains under active study. This episode helps you understand how MSCs may offer a more balanced and less aggressive approach to managing MS and improving long-term stability.

Blog Link: How Mesenchymal Stem Cells May Help Immune Balance in Relapsing-Remitting MS

Transcript

SPEAKER_00 0:00

Welcome to the Cyrona Cell Podcast. You know, usually when we talk about a medical diagnosis, there's this expectation of um absolute precision, right? Like it's an engineering problem. You break your arm, the x-ray shows the crack, the doctor points right to it, and they fix it.

SPEAKER_01 0:16

Right. Yeah, it's a very straightforward mechanical fix.

SPEAKER_00 0:19

Exactly. But imagine your body is a house. And instead of a broken window that you can easily just see and replace, the wiring inside the walls is it's slowly stripping itself bare. It's sparking these unpredictable fires in totally random rooms.

SPEAKER_01 0:33

That's a really good way to visualize it.

SPEAKER_00 0:35

Right. And that is the invisible, terrifying reality of relapsing, remitting multiple sclerosis. You step into this diagnostic and therapeutic landscape that is completely murky.

SPEAKER_01 0:46

Oh, it is the absolute definition of diagnostic muddy waters. I mean, the immune system is essentially fighting a ghost. And because the damage is often silent, you know, it's happening deep within the central nervous system.

SPEAKER_00 0:56

So you can't even see it right away.

SPEAKER_01 0:58

Exactly. Standard imaging might not actually capture the full extent of the physiological chaos until significant function is already lost.

SPEAKER_00 1:05

Which makes navigating treatments incredibly difficult because the sheer volume of information and honestly misinformation out there can be totally exhausting.

SPEAKER_01 1:12

It really is overwhelming for patients.

SPEAKER_00 1:14

Yeah, and if you are dealing with an autoimmune issue yourself, or maybe supporting someone who is, you know exactly what I mean. So the mission for our deep dive today is to really cut through that heavy medical jargon.

SPEAKER_01 1:26

We definitely need to do that.

SPEAKER_00 1:28

For sure. We're synthesizing a clinical article on how missing chymal stem cells or MSEs could be a total game changer for immune balance in relapsing remitting MS.

SPEAKER_01 1:39

And this is such an important topic right now.

SPEAKER_00 1:42

It really is. And to ground this in actual reality, we're pairing that science with operational details directly from Sorona cell. They're a doctor-led regenerative medicine center based in Malaysia with a service area that actually caters to a lot of international patients, too. So we can see how this biology is actually applied in a real clinical setting.

SPEAKER_01 2:01

Getting out of the theoretical lab space is so important here. I mean, we want to understand the exact biological levers these therapies pull inside the body. But equally, we need to know what a highly structured, scientifically rigorous stem cell clinic actually looks like.

SPEAKER_00 2:17

Right, when you peel back all the glossy marketing.

SPEAKER_01 2:19

Precisely. You have to look past the hype.

SPEAKER_00 2:21

Okay, let's unpack this. Before we even touch the clinical applications, we have to look at the battlefield itself, right?

SPEAKER_01 2:27

Yeah.

SPEAKER_00 2:27

We need to understand the mechanics of relapsing remitting MS and why traditional approaches to treating it are, well, they're starting to face some serious scrutiny.

SPEAKER_01 2:37

Looking at it as a battlefield is highly accurate. In relapsing remitting MS, your immune system essentially just loses its self-tolerance. It starts identifying the myelin sheath as a foreign invader.

SPEAKER_00 2:47

And the myelin sheath, that's the that's the insulation.

SPEAKER_01 2:50

Yes, exactly. Myelin is the protective fatty layer that insulates the nerve fibers in your brain and spinal cord. Without that insulation, the electrical signals misfire, or they slow down, or they simply just don't get through at all. Yeah. And that leads to the communication breakdown between the brain and the body, which results in symptoms like vision loss, extreme fatigue, or motor control issues.

SPEAKER_00 3:13

Aaron Ross Powell And the relapsing remitting part of the diagnosis really dictates the patient experience, doesn't it? Like it is not just a steady, predictable decline, it's a cycle.

SPEAKER_01 3:23

It's very cyclical. Yeah.

SPEAKER_00 3:24

You have these severe relapses where the immune cells become highly active, basically breaching the blood-brain barrier and causing massive localized inflammation. But then you have remission.

SPEAKER_01 3:35

Right, the quiet periods.

SPEAKER_00 3:36

Yeah, and the overt symptoms might improve or disappear, but the underlying disease process that's smoldering inflammation is often just continuing silently in the background.

SPEAKER_01 3:46

Precisely. The war doesn't end just because the major clinical flare-ups have paused. And because of this ongoing immune dysfunction, traditional therapies, specifically disease-modifying therapies, have historically focused on blunt force.

SPEAKER_00 4:00

Like just shutting it all down.

SPEAKER_01 4:01

Pretty much. The strategy has largely been about suppressing the immune system heavily just to stop those acute attacks from happening.

SPEAKER_00 4:08

Aaron Powell Which, I mean, that makes sense purely from the perspective of stopping the immediate damage, right? But it comes with a massive physiological cost.

SPEAKER_01 4:15

Trevor Burrus, Jr.: Huge cost, yes.

SPEAKER_00 4:17

Aaron Ross Powell So are traditional treatments basically like hitting the mute button on a stereo? Like you stop the terrible feedback loop of the MS attack, but now you can't hear anything else either. Your immune system is shut down, leaving you completely vulnerable to everyday infections.

SPEAKER_01 4:33

That's a really accurate way to look at it. Aaron Powell Right.

SPEAKER_00 4:35

Whereas based on these sources, MSCs, mesenchymal stem cells, they act more like a mixing board. You know, you're subtly adjusting the volume of very specific immune cells without muting the whole system.

SPEAKER_01 4:47

What's fascinating here is how well that mixing board analogy holds up at the cellular level. MSCs, which are adult stem cells found in tissues like bone marrow, fat, and the umbilical cord, they don't just blanket suppress the immune system. Their defining characteristic is immune modulation. When they are introduced into an inflamed environment, they literally physically interact with the specific T cells and B cells that are driving the MS attacks. And they basically negotiate with them.

SPEAKER_00 5:13

Aaron Powell Wait, meaning they don't just kill off the immune cells, they actually alter their behavior.

SPEAKER_01 5:18

Aaron Powell Exactly. They change how the cells are acting.

SPEAKER_00 5:20

Aaron Powell So instead of carpet bombing the immune system, they like turn down the treble on the aggressive uh effector T cells and then boost the base on the regulatory T cells, which are the ones responsible for maintaining peace.

SPEAKER_01 5:32

Aaron Powell That is exactly the mechanism. We are talking about a major shift from suppression to modulation. The clinical sources detail how MSCs prompt a shift in macrophages, that's another type of immune cell, from a pro-inflammatory state, which is known as M1, to an anti-inflammatory state known as M2.

SPEAKER_00 5:51

Oh, I see.

SPEAKER_01 5:52

Yeah. So we are moving away from trying to turn the body's defenses completely off and moving toward giving the body the biological signals it actually needs to regulate itself properly again.

SPEAKER_00 6:02

Aaron Powell But you know, knowing that these cells offer this incredible mixing board capability is really only half the battle. I want to look at the exact biological levers these MSCs are pulling inside the body to actually achieve that M1 to M2 shift or that T cell regulation.

SPEAKER_01 6:16

It's incredibly complex.

SPEAKER_00 6:17

Aaron Powell I bet. Like how are they physically doing this? Because obviously they aren't tiny intelligent machines making conscious decisions in there.

SPEAKER_01 6:24

Aaron Powell No, no. They operate through a really sophisticated exchange of biochemical signals. When MSCs detect high levels of inflammation, they respond by releasing a complex cocktail of biological signaling molecules. Okay. We are talking about specific cytokines and these microscopic vesicles called exosomes. You can think of these exosomes as basically chemical text messages sent directly to the surrounding immune cells and damaged tissues. Trevor Burrus, Jr.

SPEAKER_00 6:51

Chemical text messages. So they are essentially flooding the local microenvironment with localized instructions.

SPEAKER_01 6:58

Yes, exactly.

SPEAKER_00 6:59

And those chemical text messages are actively telling the aggressive immune cells to stand down, which leads to the measurably reduced inflammation markers we see in the clinical data over time.

SPEAKER_01 7:08

Aaron Powell Exactly. And the sources heavily emphasize another crucial outcome of this signaling process, which is the neuroprotective effect.

SPEAKER_00 7:16

Right, the neuroprotective effect.

SPEAKER_01 7:17

Yeah. By calming that acute inflammation, MSCs create a highly supportive, nutrient-rich environment. And that protects the existing surviving nerve cells from sustaining further damage from all those toxic inflammatory byproducts.

SPEAKER_00 7:30

Hey, wait. Do these stem cells physically travel to the brain and magically turn into brand new nerve cells to replace the damaged ones? Right. Because this is where regenerative medicine often gets wildly misrepresented online.

SPEAKER_01 7:43

I am so glad you asked that. It is critical we clear that up because it is arguably the single biggest misconception in this entire field.

SPEAKER_00 7:50

It really is. You see it everywhere.

SPEAKER_01 7:51

You do. But no, MSCs do not magically transform into brand new neurons to replace the damaged ones. That is simply not how adult mesenchymal stem cells function in this context.

SPEAKER_00 8:02

Okay, so if they aren't becoming the new nerves, how does the neuroprotective part actually result in healing? Like what are they doing?

SPEAKER_01 8:09

Think of it like a major construction site. If a historic building is damaged in a storm, the MSCs are not the new bricks. They are the site managers and the construction workers who show up, set up the protective scaffolding around the building, clear away the debris, which in the body means clearing out the inflammatory toxins, and they bring in the blueprints.

SPEAKER_00 8:27

Oh, that makes so much sense.

SPEAKER_01 8:29

Yeah. And by doing this, they allow the body's local native repair mechanisms like oligodendrocytes, which are the cells that naturally make myelin to actually do their job safely. They basically provide the optimal conditions for the body to heal itself.

SPEAKER_00 8:44

That is such a fundamental distinction. They are the scaffolding and the site managers, not the bricks.

SPEAKER_01 8:49

Exactly.

SPEAKER_00 8:50

So now that we know how this precise modulating scaffolding works biologically, how does this stack up against the more aggressive stem cell treatments we see making headlines? Because when people hear stem cells for MS, they are usually thinking of something radically different than what you just described.

SPEAKER_01 9:06

Yes, the public consciousness is largely focused on hematopoietic stem cell transplantation, or HSCT. And it is vital to understand that HSCT uses an entirely different biological mechanism and it carries a completely different risk profile.

SPEAKER_00 9:20

Right. Our sources draw a very stark line between the two. HSCT aims to entirely reset the immune system. Like you extract the patient's blood stem cells, essentially wipe out their existing faulty immune system using heavy chemotherapy.

SPEAKER_01 9:35

Which is very intense.

SPEAKER_00 9:36

Super intense. And then infuse those blood cells back in to rebuild the system from scratch. It is intensive, it is incredibly aggressive, and the lived experience for the patient is grueling. I mean, you are spending weeks highly vulnerable to infection because your body literally has zero defense against even a common cold.

SPEAKER_01 9:53

The clinical reality of MSC therapy is quite different, thankfully. Because MSCs focus purely on regulation and modulation rather than destruction and rebuilding. The treatment is consistently shown in clinical trials to be very well tolerated.

SPEAKER_00 10:06

That's a huge relief.

SPEAKER_01 10:08

It is. The adverse events we see in the data are generally mild and temporary.

SPEAKER_00 10:11

We're talking about what fatigue, perhaps a mild transient fever or some localized discomfort at the IV or injection site, right? It's a completely different patient experience because you aren't poisoning the immune system first.

SPEAKER_01 10:23

Correct. You are introducing a regulatory element, you know, not initiating a biological reboot.

SPEAKER_00 10:30

Here's where it gets really interesting. If we look at this through our earlier analogies, HSCT is basically like rebooting a completely frozen computer by just yanking the power cord right out of the wall.

SPEAKER_01 10:41

Yes.

SPEAKER_00 10:41

It might clear the air, but it's violent. It stresses the hardware and it carries significant risks. MSEs, on the other hand, are like running a background diagnostic scam to find and fix a software bug while the computer is actually still up and running. Is this why MSEs are being viewed in the research as a long-term stability strategy rather than a dramatic one-time quick fix?

SPEAKER_01 11:02

This raises an important question about how we view and manage chronic autoimmune diseases. The goal with MSCs is absolutely long-term stability through natural immune balance. But you know, we have to be scientifically grounded here. Of course. Not all MS patients respond the exact same way to this biological signaling. The clinical trials show that patients with relapsing remitting MS tend to see the most benefit.

SPEAKER_00 11:25

And that's because there is still an active, fluctuating inflammatory process for the MSCs to actually modulate and calm down.

SPEAKER_01 11:32

Right. Precisely. The mixing board only works if there's a signal to adjust. But for patients with more advanced forms, like secondary progressive MS, the disease profile changes entirely.

SPEAKER_00 11:43

Oh, I see.

SPEAKER_01 11:44

In those later stages, the active inflammation has largely died down, and the nerve damage is more entrenched and degenerative. So the MSCs might arrive at the construction site, but the environment is just too degraded for the scaffolding to help. This makes personalized medical evaluation absolutely critical.

SPEAKER_00 12:01

Aaron Powell Which perfectly highlights the gap between understanding the theoretical science and actually accessing it safely. I mean, knowing that these cells offer this incredible scaffolding capability is great, but if a patient actually wants to utilize them, they are stepping into a global market that's heavily populated by unregulated clinics promising the noon.

SPEAKER_01 12:19

There's a real minefield out there.

SPEAKER_00 12:20

It is. So how do you find the real science? And I guess that brings us to our operational source for today, Sorona Cell.

SPEAKER_01 12:26

Right. Sorona Cell is a regenerative medicine center located in Kuala Lumpur, Malaysia. They are a doctor-led facility and they cater to local patients as well as a really large international base, drawing people from regions like Australia and the Middle East.

SPEAKER_00 12:43

Yeah, and even their name sets a very specific, deliberate tone. Sorona is named after a Celtic goddess of health and protection. And their documentation explicitly states that this reflects an anti-quickfix, science-led ethos.

SPEAKER_01 12:59

Which is really refreshing.

SPEAKER_00 13:01

Totally. They are clearly trying to position themselves as the complete antithesis of the Wild West stem cell clinics you read those terrifying horror stories about.

SPEAKER_01 13:09

But that ethos has to be backed up by laboratory standards, right? And their operational protocols are actually quite revealing. They specifically utilize WJMSCs. And those are. These are early passage mesenchymal stem cells derived from Wharton's jelly, which is the tissue inside an umbilical cord.

SPEAKER_00 13:24

Let's break that down for a second because early cleanage isn't just a marketing buzzword, right? It has massive biological implications.

SPEAKER_01 13:31

Absolutely massive.

SPEAKER_00 13:32

Because when cells divide too many times in a lab setting to artificially multiply them, they undergo cellular senescence. They get old, they get tired, and they lose their vitality. So early passage means Cironacell is using cells that are biologically younger, much more robust, and haven't exhausted their modulating potential, correct?

SPEAKER_01 13:51

That is exactly right. You want cells that have maximum therapeutic potency when they actually enter the body. And, you know, just as important as the cell age is the environment they're processed in.

SPEAKER_00 14:01

Right, for lab standards.

SPEAKER_01 14:02

Exactly. Cyronacell processes these WJMSCs in BSL2 laboratories, that's biosafety level two under CGMP, which stands for current good manufacturing practice, and ISO 9001 certified quality systems.

SPEAKER_00 14:16

And again, translating those acronyms into actual patient value. Yeah. CGMP means they aren't just mixing things in a back room somewhere.

SPEAKER_01 14:24

No, not at all.

SPEAKER_00 14:24

It means highly filtered air, strict sterility protocols, and tracking every single vial for identity and viability. It guarantees you're getting a clean, consistent, and highly regulated biological product, which basically minimizes the risk of contamination or adverse reactions.

SPEAKER_01 14:39

Furthermore, they source these umbilical cords ethically, strictly from healthy, full-term deliveries with complete maternal donor consent and rigorous infectious disease screening.

SPEAKER_00 14:49

Which is huge. I also want to highlight what they explicitly do not do, because this is where a lot of the ethical and medical controversy in stem cells lies. They do not use embryonic stem cells, and they do not use experimental induced pluripotent stem cells.

SPEAKER_01 15:04

Right, those carry totally different risks.

SPEAKER_00 15:06

Exactly. They are strictly using these mature adult MSCs, and their delivery methods align with that safety-first approach, too. We are talking about minimally invasive procedures like IV infusions or targeted injections. There is no aggressive open surgery involved in their standalone protocols.

SPEAKER_01 15:24

It is entirely designed to introduce those cellular site managers into the body with the least amount of trauma possible, you know, treating it as an outpatient or minimally invasive procedure.

SPEAKER_00 15:33

But wait, when I hear about an international stem cell clinic where people fly in from Australia or the Middle East for treatment, my miracle cure alarm bells immediately go off.

SPEAKER_01 15:41

That's a very fair reaction.

SPEAKER_00 15:43

Right. Medical tourism is an industry heavily built on false hope and desperate patience. So how do we know a place like Sorona Cell isn't just handing these Ivy bags out to anyone who shows up with a credit card?

SPEAKER_01 15:56

Well, if we connect this to the bigger picture, the barrier to entry is exactly what separates a legitimate medical center from a stem cell mill. Cerona Cell places a massive emphasis on what they term transparent advice.

SPEAKER_00 16:08

Okay, meaning what? Exactly.

SPEAKER_01 16:10

Meaning they position their MSC therapy strictly as an adjunct to specialist care. It is not a replacement for your neurologist, it's not a substitute for acute emergency treatment, and it is most certainly not framed as a miracle cure.

SPEAKER_00 16:22

Aaron Powell Oh, that's interesting. The documentation actually makes it incredibly clear. Their medical team, which includes physicians from internal medicine, neurology, and rehabilitation, they review every single individual case.

SPEAKER_01 16:33

Yes, every single one.

SPEAKER_00 16:34

And if they believe a patient is unlikely to benefit, perhaps because they have that advanced secondary progressive MS we talked about earlier, where the window for effective immune modulation is already closed, they will honestly just turn the patient away.

SPEAKER_01 16:48

And that willingness to say no is the hallmark of ethical regenerative medicine. Their stated operational priority is long-term trust and coordinated care. They track patient outcomes, they monitor for side effects with ongoing follow-up, and they integrate their therapies with the patient's wider existing care plan.

SPEAKER_00 17:07

So they're treating the whole picture.

SPEAKER_01 17:08

Exactly. They aren't trying to sell a one-time magic procedure. They are bringing the complex clinical science of MSCs out of the laboratory and into the real world with the deep respect and caution it actually requires.

SPEAKER_00 17:21

So what does this all mean? We have covered some seriously dense biological ground today. We started by looking at the chaotic, unpredictable battlefield of relapsing remitting MS, where the immune system just strips away the nervous system's wiring.

SPEAKER_01 17:34

It's a devastating process.

SPEAKER_00 17:35

It is. But we learned that instead of just hitting the mute button and wiping out the entire immune system with harsh chemicals, mesenclamyl stem cells offer an elegant, modulating mixing board solution. Through chemical text messages like exosomes, they act as cellular site managers. They bring down the localized inflammation and set up the scaffolding for the body's natural repair mechanisms to finally take over.

SPEAKER_01 17:58

And importantly, we saw how that intricate biology is safely translated into real-world medicine. By looking at the operational protocols of Cyronicell, we understand that legitimate access to this kind of therapy requires stringent ethical sourcing, elite CGMP laboratory standards to ensure self-nality, and most critically, a multidisciplinary medical team that actually relies on data and is willing to say no if the treatment just isn't clinically appropriate.

SPEAKER_00 18:23

Exactly. And why does this matter to you? Whether you are personally navigating an autoimmune diagnosis, supporting a family member who is, or honestly just fascinated by the rapid advancements in regenerative medicine, understanding this fundamental difference between blunt immune suppression and intelligent immune modulation gives you a totally powerful new lens for evaluating healthcare options.

SPEAKER_01 18:46

It really arms patients with knowledge.

SPEAKER_00 18:48

It does. It changes the types of questions you ask your doctors. It fundamentally changes how you view the capabilities of your own biology.

SPEAKER_01 18:56

It is a total paradigm shift. We are moving away from fighting the body's responses and finally learning how to effectively negotiate with them.

SPEAKER_00 19:03

It really is incredible. And that leaves us with a fascinating, slightly provocative thought to take away today. We have seen how adult stem cells like MSEs can act as intelligent cellular diplomats to negotiate with and balance an immune system that's severely afflicted by multiple sclerosis. If they can deploy chemical messengers to calm that level of severe targeted inflammation, what other silent chronic inflammations in our bodies, you know, the ones driving things like heart disease or premature aging, might these cells be capable of resolving in the future? Could our own native biology actually hold the ultimate diplomatic key to ending autoimmune disease entirely? Something to think about.